Covid19, Diabetes, Obesity
Conditions
Keywords
Obesity Counseling, telemedicine
Brief summary
The overarching goal of this proposal is to understand the comparative effectiveness of obesity counseling as covered by CMS in improving weight loss for adults either with or at high risk of type 2 diabetes. CMS and most insurers now include obesity screening and counseling benefits, with no cost sharing to patients. Since overweight patients are at highest risk for diabetes, improved weight management services could prevent diabetes and its negative health outcomes. Beneficiaries with obesity are eligible for up to 20 face-to-face visits for weight counseling in the primary care setting. The investigators propose comparing weight and diabetes outcomes in three states using EHR and claims data before and after this policy was implemented by leveraging the novel infrastructure of the Patient-Centered Outcomes Research Institute-funded PaTH Clinical Data Research Network. Following developments during the COVID-19 pandemic, the investigators further plan to leverage our study infrastructure across five health systems to understand the comparative effectiveness of telemedicine approaches for providing outpatient care for patients with or at risk of type 2 diabetes and how these approaches impact the subgroup of patients with COVID-19.
Detailed description
Aim 1: Evaluate the impact of universal preventive service coverage for obesity screening and counseling on weight loss, diabetes incidence, and diabetes outcomes, in patients with diabetes or at high risk for diabetes (defined by body mass index (BMI) ≥ 25). The investigators will determine how the annual probability of receiving obesity and/or nutritional counseling (as defined by Current Procedural Terminology (CPT) code) changed pre- and post-policy across all insurers in a cohort of patients with diabetes and at high risk for diabetes. The investigators hypothesize that individual patients are more likely to receive counseling following coverage implementation. Further, the investigators hypothesize that patients who receive a greater number of face-to-face visits will have greater weight loss compared to those who receive fewer visits. Aim 2: Compare patient weight loss and diabetes-related outcomes among those who receive obesity screening and counseling to those who do not, following implementation of preventive service coverage. The investigators will examine post-policy impact of obesity screening and counseling in a cohort of patients with diabetes and at high risk for diabetes. Specific outcomes to be examined include weight loss, diabetes incidence, and diabetes outcomes (including hemoglobin A1c, controlled blood pressure, use of a statin medication). Further, the investigators will determine patient characteristics, including demographics (age, race/ethnicity, rurality), and practice characteristics, including provider type, and their impact on receiving/providing obesity screening and counseling. Understanding patient and practice characteristics most likely to engage in obesity counseling can identify best practices and inform how to increase engagement by both patients and providers. Aim 3: To understand the impact of telemedicine access (telephonic and/or virtual visits) compared to no telemedicine visits for outpatient care for patients with, or at risk of, type 2 diabetes during the pandemic on patient-centered outcomes including hemoglobin A1c and healthcare utilization, with sub-group analysis of patients with COVID-19; Aim 4: To evaluate the risk of severe COVID-19 disease (defined by hospitalization and mortality) in patients with diabetes and/or elevated BMI, with a focus on identifying modifiable factors (i.e., medication use, treatment timeline/location, chronic comorbid conditions) and associated with improved outcomes to inform immediate intervention and future study.
Interventions
This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
Sponsors
Study design
Eligibility
Inclusion criteria
Patients with Diabetes * Ages 18 and older * Indication of Type 2 Diabetes as defined using a clinically validated algorithm: type 2 diabetes mellitus on the problem list, diabetes-specific medications, hemoglobin A1c (HbA1c) results \> 6.5%, or one inpatient diagnosis code or two out-patient diagnosis codes for type 2 diabetes (ICD-9 codes 250.xx) * patients who have either: (1) visited a primary care doctor from one of the PaTH health systems in the past 3 years (since January 1, 2012), or (2) for whom claims data are available Patients with Pre-Diabetes (At risk): * Ages 18 and older * BMI \> 25 kg/m2 * patients who have either: (1) visited a primary care doctor from one of the PaTH health systems in the past 3 years (since January 1, 2012), or (2) for whom claims data are available Patients with COVID-19: * Ages 18 and older * Patients with a diagnosis of COVID-19
Exclusion criteria
* Patients under the age of 18
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Diagnosed With COVID-19 Who Were Hospitalized | 1 year | Number of Participants Diagnosed with COVID-19 Who Were Hospitalized in both the diabetes and pre-diabetes cohorts. |
| Number of Participants Who Used the Intensive Behavioral Therapy (IBT) Service | 11 years | Number of patients who utilized IBT services was assessed in both the diabetes and pre-diabetes cohorts using code G0447. |
| Change in Weight During Counseling Program | 11 years | Weight change during counseling and/or % of weight change during program and maintained over remaining time period will be assessed in both the diabetes and pre-diabetes cohorts. |
| Hemoglobin A1c | 1 year | A1c of patients who received a telehealth visit and COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Who Received Telehealth and Were Hospitalized With a COVID-19 Diagnosis | 1 year | Number of patients who received telehealth and were hospitalized with a COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts. |
| Number of Patients With Uncontrolled Blood Pressure | 11 years | The number of patients with uncontrolled blood pressure (SBP \> 140, DBP \> 90 all the time, defined for 1-year prior to first IBTb visit, and 1-year after) in the diabetes and pre-diabetes cohorts |
| Number of Patients With Uncontrolled Hemoglobin A1c | 11 years | The number of patients with uncontrolled hemoglobin A1c (HbA1cc \> 9 any time, defined for 1-year prior to first IBTb visit, and 1-year after) in the diabetes and pre-diabetes cohorts. |
| Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death | 1 year | Incidence of ICU admission, ventilator use, or death in patients with a COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts. |
Participant flow
Recruitment details
Participants' data was analyzed as part of a secondary data analysis analyzing de-identified EHR and Claims data. Participants did not consent to participate in this study.
Pre-assignment details
Participants were not randomized for this study.
Participants by arm
| Arm | Count |
|---|---|
| Diabetes During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
Weight Counseling: This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
Telemedicine: This is a natural experiment which will observe the impact of telemedicine approaches for providing outpatient care for patients with or at risk of type 2 diabetes | 567 |
| Pre-Diabetes The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
Weight Counseling: This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes. | 2 |
| Total | 569 |
Baseline characteristics
| Characteristic | Diabetes | Pre-Diabetes | Total |
|---|---|---|---|
| Age, Customized Age 18-24 years | 10,371 Participants | 259,691 Participants | 270062 Participants |
| Age, Customized Age 25-34 years | 23,169 Participants | 355,885 Participants | 379054 Participants |
| Age, Customized Age 35-44 years | 51,885 Participants | 340,065 Participants | 391950 Participants |
| Age, Customized Age 45-54 years | 105,646 Participants | 374,446 Participants | 480092 Participants |
| Age, Customized Age 55-64 years | 151,061 Participants | 346,075 Participants | 497136 Participants |
| Age, Customized Age 65-74 years | 131,104 Participants | 224,386 Participants | 355490 Participants |
| Age, Customized Age >75 years | 94,672 Participants | 153,708 Participants | 248380 Participants |
| BMI | 32.9 kg/m^2 STANDARD_DEVIATION 7.9 | 30.9 kg/m^2 STANDARD_DEVIATION 6.2 | 31.55 kg/m^2 STANDARD_DEVIATION 7.14 |
| Diastolic Blood Pressure | 75.0 mm Hg STANDARD_DEVIATION 7.7 | 76.6 mm Hg STANDARD_DEVIATION 7.4 | 75.24 mm Hg STANDARD_DEVIATION 10.67 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 29,211 Participants | 105,438 Participants | 134649 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 514,125 Participants | 1,855,612 Participants | 2369737 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 24,572 Participants | 93,206 Participants | 117778 Participants |
| Hemoglobin A1c | 7.0 mg/dL | 5.6 mg/dL | 6.9 mg/dL |
| Race/Ethnicity, Customized Race American Indian or Alaska Native | 1,860 Participants | 4,725 Participants | 6585 Participants |
| Race/Ethnicity, Customized Race Asian | 10,809 Participants | 35,410 Participants | 46219 Participants |
| Race/Ethnicity, Customized Race Black | 79,732 Participants | 216,860 Participants | 296592 Participants |
| Race/Ethnicity, Customized Race Multiple Race | 397 Participants | 1,879 Participants | 2276 Participants |
| Race/Ethnicity, Customized Race Native Hawaiin or Other Pacific Islander | 1,311 Participants | 4,413 Participants | 5724 Participants |
| Race/Ethnicity, Customized Race Other/Missing | 34,851 Participants | 123,202 Participants | 158053 Participants |
| Race/Ethnicity, Customized Race White | 438,948 Participants | 1,667,767 Participants | 2106715 Participants |
| Region of Enrollment United States Missing | 66,297 Participants | 216,793 Participants | 283090 Participants |
| Region of Enrollment United States Rural | 31,402 Participants | 92,934 Participants | 124336 Participants |
| Region of Enrollment United States Urban | 470,209 Participants | 1,744,529 Participants | 2214738 Participants |
| Sex/Gender, Customized Sex Female | 287,725 Participants | 1,167,327 Participants | 1455052 Participants |
| Sex/Gender, Customized Sex Male | 280,170 Participants | 886,884 Participants | 1167054 Participants |
| Sex/Gender, Customized Sex Other/Missing | 13 Participants | 45 Participants | 58 Participants |
| Systolic Blood Pressure | 130.4 mm Hg STANDARD_DEVIATION 12.1 | 126.0 mm Hg STANDARD_DEVIATION 11.9 | 127.03 mm Hg STANDARD_DEVIATION 17.07 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Change in Weight During Counseling Program
Weight change during counseling and/or % of weight change during program and maintained over remaining time period will be assessed in both the diabetes and pre-diabetes cohorts.
Time frame: 11 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Diabetes | Change in Weight During Counseling Program | 206.8 lbs | Standard Deviation 55 |
| Pre-Diabetes | Change in Weight During Counseling Program | 194.8 lbs | Standard Deviation 44.9 |
Hemoglobin A1c
A1c of patients who received a telehealth visit and COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts.
Time frame: 1 year
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Diabetes | Hemoglobin A1c | 6.6 mmol/mol | Standard Deviation 1.5 |
| Pre-Diabetes | Hemoglobin A1c | 6.6 mmol/mol | Standard Deviation 1.5 |
Number of Participants Diagnosed With COVID-19 Who Were Hospitalized
Number of Participants Diagnosed with COVID-19 Who Were Hospitalized in both the diabetes and pre-diabetes cohorts.
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Participants Diagnosed With COVID-19 Who Were Hospitalized | 1,025 Participants |
| Pre-Diabetes | Number of Participants Diagnosed With COVID-19 Who Were Hospitalized | 1,379 Participants |
Number of Participants Who Used the Intensive Behavioral Therapy (IBT) Service
Number of patients who utilized IBT services was assessed in both the diabetes and pre-diabetes cohorts using code G0447.
Time frame: 11 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Participants Who Used the Intensive Behavioral Therapy (IBT) Service | 2417 Participants |
| Pre-Diabetes | Number of Participants Who Used the Intensive Behavioral Therapy (IBT) Service | 3731 Participants |
Number of Patients Who Received Telehealth and Were Hospitalized With a COVID-19 Diagnosis
Number of patients who received telehealth and were hospitalized with a COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts.
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Patients Who Received Telehealth and Were Hospitalized With a COVID-19 Diagnosis | 639 Participants |
| Pre-Diabetes | Number of Patients Who Received Telehealth and Were Hospitalized With a COVID-19 Diagnosis | 838 Participants |
Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death
Incidence of ICU admission, ventilator use, or death in patients with a COVID-19 diagnosis in both the diabetes and pre-diabetes cohorts.
Time frame: 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death | 586 Participants |
| Pre-Diabetes | Number of Patients With a COVID-19 Diagnosis and ICU Use, Ventilator Use, or Death | 500 Participants |
Number of Patients With Uncontrolled Blood Pressure
The number of patients with uncontrolled blood pressure (SBP \> 140, DBP \> 90 all the time, defined for 1-year prior to first IBTb visit, and 1-year after) in the diabetes and pre-diabetes cohorts
Time frame: 11 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Patients With Uncontrolled Blood Pressure | 300,665 Participants |
| Pre-Diabetes | Number of Patients With Uncontrolled Blood Pressure | 928,366 Participants |
Number of Patients With Uncontrolled Hemoglobin A1c
The number of patients with uncontrolled hemoglobin A1c (HbA1cc \> 9 any time, defined for 1-year prior to first IBTb visit, and 1-year after) in the diabetes and pre-diabetes cohorts.
Time frame: 11 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Diabetes | Number of Patients With Uncontrolled Hemoglobin A1c | 79,046 Participants |
| Pre-Diabetes | Number of Patients With Uncontrolled Hemoglobin A1c | 164 Participants |